PHIO PHARMACEUTICALS CORP. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PHIO PHARMACEUTICALS CORP. (PHIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $278.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $278.00K, a 445.10% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $318.00K, a 639.53% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $113.00K, a 117.31% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $51.00K, a 240.00% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $481.00K, a 227.21% increase from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $147.00K, a 51.49% decline from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $303.00K, a 26.81% decline from fiscal 2022.
- PHIO PHARMACEUTICALS CORP. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $414.00K, a 13.75% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $278.00K 10-Q · filed 2026-08-06 | $596.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $318.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $481.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $113.00K 10-Q · filed 2025-11-13 | $164.00K derived: sum of 2 quarters · filed 2026-08-06 | $207.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $51.00K 10-Q · filed 2026-08-06 | $94.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $43.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $147.00K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $52.00K 10-Q · filed 2025-11-13 | $67.00K derived: sum of 2 quarters · filed 2025-11-13 | $99.00K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $15.00K 10-Q · filed 2025-11-13 | $47.00K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $32.00K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $303.00K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $89.00K 10-Q · filed 2024-11-14 | $183.00K derived: sum of 2 quarters · filed 2024-11-14 | $294.00K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $94.00K 10-Q · filed 2024-11-14 | $205.00K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $111.00K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $414.00K 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $103.00K 10-Q · filed 2023-11-09 | $186.00K derived: sum of 2 quarters · filed 2023-11-09 | $372.00K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $83.00K 10-Q · filed 2023-11-09 | $269.00K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $186.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $480.00K 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $143.00K 10-Q · filed 2022-11-10 | $275.00K derived: sum of 2 quarters · filed 2022-11-10 | $342.00K derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $132.00K 10-Q · filed 2022-11-10 | $199.00K derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $67.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $136.00K 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $37.00K 10-Q · filed 2021-11-10 | $67.00K derived: sum of 2 quarters · filed 2021-11-10 | $110.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $30.00K 10-Q · filed 2021-11-10 | $73.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $43.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $300.00K 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $47.00K 10-Q · filed 2020-11-10 | $109.00K derived: sum of 2 quarters · filed 2020-11-10 | $269.00K derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $62.00K 10-Q · filed 2020-11-10 | $222.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $160.00K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $282.00K 10-K · filed 2020-03-26 | |||
| 2018-09-30 | $39.00K 10-Q · filed 2019-11-12 | $76.00K derived: sum of 2 quarters · filed 2019-11-12 | $117.00K derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $37.00K 10-Q · filed 2019-11-12 | $78.00K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $41.00K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $314.00K 10-K · filed 2019-03-27 | |||
| 2016-12-31 | $756.00K 10-K · filed 2018-03-26 | |||
| 2015-12-31 | $1.53M 10-K · filed 2017-03-30 | |||
| 2014-12-31 | $1.85M 10-K · filed 2016-03-30 | |||
| 2013-12-31 | $473.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $1.98M 10-K · filed 2015-03-30 | ||
| 2013-09-30 | $1.51M 10-Q · filed 2013-11-14 | |||
| 2013-03-31 | $628.00K 10-Q · filed 2013-05-15 | $925.00K derived: sum of 2 quarters · filed 2014-03-28 | $1.22M derived: sum of 3 quarters · filed 2014-03-28 | |
| 2012-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $594.00K derived: sum of 2 quarters · filed 2014-03-28 | $968.00K 10-K · filed 2014-03-28 | |
| 2012-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | $671.00K 10-Q · filed 2012-11-13 | ||
| 2012-06-30 | $374.00K 10-Q · filed 2012-08-14 | |||
| 2011-12-31 | $122.00K 10-K · filed 2014-03-28 | |||
| 2010-12-31 | $4.37M 10-K · filed 2014-03-28 | |||
| 2009-12-31 | $4.20M 10-K · filed 2014-03-28 | |||
| 2008-12-31 | $3.82M 10-K · filed 2014-03-28 | |||
| 2007-12-31 | $1.81M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |